Jingfeng Pharmaceutical(SZ:000908) Zheng Quan Zhi Xing·2025-07-17 16:10Summary of Key Points Core Viewpoint - The company, Hunan Jingfeng Pharmaceutical Co., Ltd., disclosed its cumulative litigation and arbitration matters over the past twelve months, revealing a total amount involved of RMB 19.5736 million, which exceeds 10% of the company's latest audited net assets, thus meeting disclosure standards [1][2]. Group 1: Litigation and Arbitration Overview - The total amount involved in litigation and arbitration matters for the company and its subsidiaries is RMB 19.5736 million, with no single case exceeding RMB 10% of the latest audited net assets [1]. - There are no undisclosed litigation or arbitration matters that should have been reported [1]. Group 2: Potential Impact on Profit - The company will actively pursue legal actions to protect its rights and recover related funds, while also responding to cases where it is a defendant [2]. - The impact of these litigation matters on the company's current and future profits remains uncertain, as some cases are still pending trial or resolution [2].